New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
06:58 EDTNBIXAbbVie reports second Elagolix Phase 3 clinical trial met co-primary endpoint
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced positive top-line results from the second of two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer pain from endometriosis. Trial results show that after six months of continuous treatment, both doses of Elagolix met the study's co-primary endpoints. Elagolix reduced scores of menstrual pain and non-menstrual pelvic pain, or NMPP, associated with endometriosis, at month three and month six, as measured by the Daily Assessment of Endometriosis Pain scale. Responder rates for the co-primary endpoints from this second Phase 3 pivotal study are consistent with results from the first Phase 3 pivotal study.
February 2, 2016
08:59 EDTNBIXLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
08:35 EDTNBIXNeurocrine begins Phase II clinical trial for NBI-98854
Subscribe for More Information
January 28, 2016
07:12 EDTNBIXAbbVie intiates enrollment in Phase 3 clinical program for Elagolix
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. These studies are designed to assess the change in menstrual blood loss utilizing the alkaline hematin method, comparing baseline to month six of treatment. Additional secondary efficacy endpoints are being evaluated; including assessing changes in fibroid volume, monthly blood loss and hemoglobin levels. Bone mineral density will also be assessed.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use